Alec Marticoff

Mr. Alec Marticoff


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
GPGrant Podhajsky
Grant Podhajsky
KMKiran Marla
Kiran Marla
AMAlec Marticoff
Alec Marticoff
KNKenny Nguyen
Kenny Nguyen
TKTanner Kempton
Tanner Kempton
DBDouglas Bennion
Douglas Bennion
Audiovestibular disorders arising from the inner ear (e.g., hearing loss, tinnitus, vertigo) are widely prevalent in the United States. Yet, medical treatments targeting the underlying pathology of these disorders remain scarce. The practice of repurposing FDA-approved drugs for new therapeutic indications has become increasingly common, offering a lower risk route to treatment development with fewer barriers to implementation, as safety profiles are already established. The renin–angiotensin system (RAS) is well known for its role in blood pressure and fluid balance, and its overactivation induces acute and chronic inflammation and oxidative stress. This review discusses existing evidence and proposed otoprotective mechanisms of RAS inhibition, specifically using angiotensin II type 1 receptor blockers (ARBs), which support the repurposing of these medications as novel treatments to affect the inner ear pathologies that underlay hearing loss, tinnitus, and vertigo.